Puma Biotechnology Inc - PBYI Company Short-Term Debt

Puma Biotechnology focuses on therapies for severe oncological pathologies, offering the drug NERLYNX to prevent disease recurrence. However, declining revenue from its primary medication limits development, necessitating strict budget management, although reserves remain sufficient. Historical price action confirms these aspects, while the specific short-term debt metric stands at 0.00.

Short-term debts represent the aggregate of all financial obligations with a maturity of less than twelve months. By analyzing the current size of short-term liabilities, an investor assesses the liquidity and interest rate sensitivity of the company. This metric sums current credits and loans, determining the burden on working capital. The value of 0.00 reflects the financial stability of Puma Biotechnology (PBYI). This allows the company to maintain a stable staff of specialists without the risk of cash flow gaps.